In a regulatory filing, Caris Life Sciences (CAI) vice chairman Brian Brille disclosed the purchase of 30,000 common shares of the company on June 20 at a price of $21 per share.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAI:
- Opening Day: Caris jumps as investors buy into ‘AI TechBio company’
- Two new option listings and nine option delistings on June 23rd
- Caris Life Sciences 23.53M share IPO priced at $21.00
- Caris Life Sciences indicated to open at $30, IPO priced at $21 per share
- Caris Life Sciences indicated to open at $28.50, IPO priced at $21